<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SULFAMETHOXAZOLE AND TRIMETHOPRIM- sulfamethoxazole and trimethoprimÂ suspensionÂ </strong><br>Preferred Pharmaceuticals, Inc.<br></p></div>
<h1>
<span class="Bold">Sulfamethoxazole and Trimethoprim Oral Suspension, USP</span><br><span class="Bold">Rx only</span><br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17"></a><a name="section-1"></a><p></p>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim oral suspension and other antibacterial drugs, sulfamethoxazole and trimethoprim oral suspension should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_1"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Sulfamethoxazole and trimethoprim oral suspension, USP is a synthetic antibacterial combination product containing 200 mg sulfamethoxazole and 40 mg trimethoprim in each teaspoonful (5 mL).<br><br>Sulfamethoxazole is <span class="Italics">N</span><span class="Sup">1</span>-(5-methyl-3-isoxazolyl)sulfanilamide; the molecular formula is C<span class="Sub">10</span>H<span class="Sub">11</span>N<span class="Sub">3</span>O<span class="Sub">3</span>S. It is a white to off-white, practically odorless, crystalline powder, tasteless compound with a molecular weight of 253.28 and the following structural formula:</p>
<div class="Figure">
<a name="id293"></a><img alt="sulfatrim-str1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bbad2036-e2a8-4c56-bb92-dea833598ebc&amp;name=bbad2036-e2a8-4c56-bb92-dea833598ebc-01.jpg">
</div>
<p>Trimethoprim is 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine; the molecular formula is C<span class="Sub">14</span>H<span class="Sub">18</span>N<span class="Sub">4</span>O<span class="Sub">3</span>. It is a white or cream-colored crystals or crystalline powder with a molecular weight of 290.3 and the following structural formula:</p>
<div class="Figure">
<a name="id302"></a><img alt="sulfatrim-str2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bbad2036-e2a8-4c56-bb92-dea833598ebc&amp;name=bbad2036-e2a8-4c56-bb92-dea833598ebc-02.jpg">
</div>
<p>Each teaspoonful (5 mL) of the oral suspension contains 200 mg sulfamethoxazole and 40 mg trimethoprim as well as the following inactive ingredients: alcohol 0.04% (v/v), carboxymethylcellulose sodium, citric acid anhydrous, colloidal silicon dioxide, FD&amp;C Red #40, flavour cherry #557, glycerin, methyl paraben, microcrystalline cellulose and carboxymethylcellulose sodium, polysorbate 80, purified water, saccharin sodium, sodium benzoate, and sorbitol solution.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_2"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. Sulfamethoxazole is metabolized in humans to at least 5 metabolites: the N<span class="Sub">4</span>-acetyl-, N<span class="Sub">4</span>-hydroxy-, 5-methylhydroxy-, N<span class="Sub">4</span>-acetyl-5-methylhydroxy-sulfamethoxazole metabolites, and an N-glucuronide conjugate. The formulation of N<span class="Sub">4</span>-hydroxy metabolite is mediated <span class="Italics">via </span>CYP2C9.<br><br>Trimethoprim is metabolized <span class="Italics">in vitro </span>to 11 different metabolites, of which, five are glutathione adducts and six are oxidative metabolites, including the major metabolites, 1- and 3-oxides and the 3- and 4-hydroxy derivatives.<br><br>The free forms of sulfamethoxazole and trimethoprim are considered to be the therapeutically active forms. <br><br><span class="Italics">In vitro </span>studies suggest that trimethoprim is a substrate of P-glycoprotein, OCT1 and OCT2, and that sulfamethoxazole is not a substrate of P-glycoprotein.<br><br>Approximately 70% of sulfamethoxazole and 44% of trimethoprim are bound to plasma proteins. The presence of 10 mg percent sulfamethoxazole in plasma decreases the protein binding of trimethoprim by an insignificant degree; trimethoprim does not influence the protein binding of sulfamethoxazole.<br><br>Peak blood levels for the individual components occur 1 to 4 hours after oral administration. The mean serum half-lives of sulfamethoxazole and trimethoprim are 10 and 8 to 10 hours, respectively. However, patients with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> exhibit an increase in the half-lives of both components, requiring dosage regimen adjustmentÂ Â (see <span class="Bold"><a href="#Section_10">DOSAGE AND ADMINISTRATION</a></span> section). Detectable amounts of sulfamethoxazole and trimethoprim are present in the blood 24 hours after drug administration. During administration of 800 mg sulfamethoxazole and 160 mg trimethoprim b.i.d., the mean steady-state plasma concentration of trimethoprim was 1.72 mcg/mL. The steady-state mean plasma levels of free and total sulfamethoxazole were 57.4 mcg/mL and 68 mcg/mL, respectively. These steady-state levels were achieved after three days of drug administration.<span class="Sup">1</span> Excretion of sulfamethoxazole and trimethoprim is primarily by the kidneys through both glomerular filtration and tubular secretion. Urine concentrations of both sulfamethoxazole and trimethoprim are considerably higher than are the concentrations in the blood. The average percentage of the dose recovered in urine from 0 to 72 hours after a single oral dose of sulfamethoxazole and trimethoprim is 84.5% for total sulfonamide and 66.8% for free trimethoprim. Thirty percent of the total sulfonamide is excreted as free sulfamethoxazole, with the remaining as N<span class="Sub">4</span>-acetylated metabolite.<span class="Sup">2</span> When administered together as sulfamethoxazole and trimethoprim, neither sulfamethoxazole nor trimethoprim affects the urinary excretion pattern of the other.<br><br>Both sulfamethoxazole and trimethoprim distribute to <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>, vaginal fluid and middle ear fluid; trimethoprim also distributes to bronchial secretion, and both pass the placental barrier and are excreted in human milk.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_2.1"></a><a name="section-3.1"></a><p></p>
<h2>Geriatric Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of sulfamethoxazole 800 mg and trimethoprim 160 mg were studied in 6 geriatric subjects (mean age: 78.6 years) and 6 young healthy subjects (mean age: 29.3 years) using a non-U.S. approved formulation. Pharmacokinetic values for sulfamethoxazole in geriatric subjects were similar to those observed in young adult subjects. The mean renal clearance of trimethoprim was significantly lower in geriatric subjects compared with young adult subjectsÂ (19 mL/h/kg vs. 55 mL/h/kg). However, after normalizing by body weight, the apparent total body clearance of trimethoprim was on average 19% lower in geriatric subjects compared with young adult subjects.<span class="Sup">3</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-3.2"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA). Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the required enzyme, dihydrofolate reductase. Thus, sulfamethoxazole and trimethoprim blocks two consecutive steps in the biosynthesis of nucleic acids and proteins essential to many bacteria.<br><br><span class="Italics">In vitro </span>studies have shown that <span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">bacterial resistance</span> develops more slowly with both sulfamethoxazole and trimethoprim in combination than with either sulfamethoxazole or trimethoprim alone.<br><br>Sulfamethoxazole and trimethoprim have been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold"><a href="#Section_3">INDICATIONS AND USAGE</a></span> section.<br><br>Aerobic gram-positive microorganisms<br><br><span class="Italics">Streptococcus pneumoniae</span><br><br>Aerobic gram-negative microorganisms<br><br><span class="Italics">Escherichia coli </span>(including susceptible enterotoxigenic <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> implicated in traveler's <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>)<br><span class="Italics">Klebsiella </span>species<br><span class="Italics">Enterobacter </span>species<br><span class="Italics">Haemophilus influenzae</span><br><span class="Italics">Morganella morganii </span><br><span class="Italics">Proteus mirabilis</span><br><span class="Italics">Proteus vulgaris</span><br><span class="Italics">Shigella flexneri </span><br><span class="Italics">Shigella sonnei </span><br><br>Other Organisms<br><br><span class="Italics">PneumocystisÂ jiroveci</span><br><br>Susceptibility Testing Methods<br><br>When available, the clinical microbiology laboratory should provide the results of <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug for treatment.<br><br><span class="Italics">Dilution Techniques</span><br><br>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method (broth or agar)<span class="Sup">4,15</span>. The MIC values should be interpreted according to the criteria provided in Table 1.<br><br><span class="Italics">Diffusion Techniques</span><br><br>Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method<span class="Sup">14,15</span>. This procedure uses paper disks impregnated with 1.25/23.75 mcg of trimethoprim and sulfamethoxazole to test the susceptibility of microorganisms to trimethoprim and sulfamethoxazole. The disc diffusion interpretive criteria are provided in Table 1.Â </p>
<p><span class="Bold">Â </span></p>
<a name="_RefID0EDLAC"></a><table>
<caption><span>Table 1: Susceptibility Test Interpretive Criteria for Trimethoprim and Sulfamethoxazole  </span></caption>
<col width="28%">
<col width="13%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="11%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2"><p class="First"><span class="Bold">Bacteria </span><br></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Minimal Inhibitory Concentration (mcg/mL)</span><br></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Zone Diameter (mm)</span><br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">S</span><br></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">I</span><br></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">R</span><br></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">S</span><br></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">I</span><br></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">R</span><br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Enterobacteriaceae </span><br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¤ 2/38<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">-<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¥ 4/76<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¥ 16<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">11 â€“ 15<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¤ 10<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Haemophilus influenzae </span><br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¤ 0.5/9.5<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1/19 â€“ 2/38<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¥ 4/76<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¥ 16<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">11 â€“ 15<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¤ 10<br></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Streptococcus pneumoniae </span><br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¤ 0.5/9.5<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1/19 â€“ 2/38<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¥ 4/76<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¥ 19<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">16 â€“ 18<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¤ 15<br></p></td>
</tr>
</tbody>
</table>
<p>A report of <span class="Italics">Susceptible </span>indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations at the site of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> necessary to inhibit growth of the pathogen. A report of <span class="Italics">Intermediate </span>indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of <span class="Italics">Resistant </span>indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site; other therapy should be selected.<br><br>Quality Control<br><br>Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay and the techniques of the individuals performing the test<span class="Sup">4,14,15</span>. Standard trimethoprim and sulfamethoxazole powder should provide the following range of MIC values noted in Table 2. For the diffusion technique using the 1.25/23.75 mcg trimethoprim and sulfamethoxazole disk the criteria in Table 2 should be achieved.</p>
<a name="_RefID0EICAE"></a><table>
<caption><span>Table 2: Acceptable Quality Control Ranges for Susceptibility Testing for Trimethoprim and Sulfamethoxazole  </span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span> </span><br></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Minimal Inhibitory </span><br><span class="Bold">Concentration (mcg/mL)</span><br></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Zone Diameter </span><br><span class="Bold">(mm)</span><br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Escherichia coli </span>ATCC 25922 <br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¤ 0.5/9.5 <br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">23â€“29 <br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Haemophilus influenzae </span>ATCC 49247 <br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.03/0.59 â€“ 0.25/4.75 <br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">24â€“32 <br></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Streptococcus pneumoniae </span>ATCC 49619 <br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.12/2.4 â€“ 1/19 <br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">20â€“28 <br></p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_3"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim oral suspension, USP and other antibacterial drugs, sulfamethoxazole and trimethoprim oral suspension, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy.<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></span><br><br>For the treatment of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms: <span class="Italics">Escherichia coli, Klebsiella </span>species, <span class="Italics">Enterobacter </span>species, <span class="Italics">Morganella morganii, Proteus mirabilis </span>and <span class="Italics">Proteus vulgaris. </span>It is recommended that initial episodes of uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> be treated with a single effective antibacterial agent rather than the combination.<br><br><span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></span><br><br>For the treatment of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> in pediatric patients due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Streptococcus pneumoniae </span>or<span class="Italics"> Haemophilus influenzae </span>when in the judgment of the physician sulfamethoxazole and trimethoprimÂ offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim oral suspension, USP in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim oral suspension, USP is not indicated for <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> or prolonged administration in <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> at any age.<br><br><span class="Bold">Acute Exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span> in Adults</span><br><br>For the treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Streptococcus pneumoniae </span>or <span class="Italics">Haemophilus influenzae </span>when a physician deems that sulfamethoxazole and trimethoprim oral suspension, USP could offer some advantage over the use of a single antimicrobial agent.<br><br><span class="Bold">Shigellosis</span><br><br>For the treatment of <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Shigella flexneri </span>and <span class="Italics">Shigella sonnei </span>when antibacterial therapy is indicated.<br><br><span class="Bold"><span class="Italics">PneumocystisÂ jiroveci <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></span></span><br><br>For the treatment of documented <span class="Italics">PneumocystisÂ jiroveci </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and for prophylaxis against <span class="Italics">P.Â jiroveci </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in individuals who are immunosuppressed and considered to be at an increased risk of developing <span class="Italics">P.Â jiroveci </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>.<br><br><span class="Bold">Traveler's <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> in Adults</span><br><br>For the treatment of travelerâ€™s <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of enterotoxigenic <span class="Italics">E. coli.</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Sulfamethoxazole and trimethoprim oral suspension is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to trimethoprim or sulfonamides, in patients with a history of drug-induced immune <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with use of trimethoprim and/or sulfonamides, and in patients with documented <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> due to <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>.<br><br>Sulfamethoxazole and trimethoprim oral suspension is contraindicated in pediatric patients less than 2 months of age. Sulfamethoxazole and trimethoprim oral suspension is also contraindicated in patients with marked <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatic damage</span> or with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> when renal function status cannot be monitored.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Section_5"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">Embryofetal Toxicity</span><br><br>Some epidemiologic studies suggest that exposure to sulfamethoxazole and trimethoprim during pregnancy may be associated with an increased risk of congenital malformations, particularly <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span>, cardiovascular malformations, urinary tract defects, oral clefts, and club foot. If sulfamethoxazole and trimethoprim is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be advised of the potential hazards to the fetus.<br><br><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> and Other Fatal Reactions</span></span><br><br>Fatalities associated with the administration of sulfonamides, although rare, have occurred due to severe reactions, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> and other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>.<br><br>Sulfonamides, including sulfonamide-containing products such as sulfamethoxazole and trimethoprim, should be discontinued at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any sign of adverse reaction. In rare instances, a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> may be followed by a more severe reaction, such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, and serious <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorders</span> (see <span class="Bold"><a href="#Section_6">PRECAUTIONS</a></span>).Â Clinical signs, such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> may be early indications of serious reactions.<br><br><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, and pulmonary infiltrates are <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> of the respiratory tract that have been reported in association with sulfonamide treatment.</p>
<p><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span><br><br>Sulfamethoxazole and trimethoprim-induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> may be an immune-mediated disorder. Severe cases of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> that are fatal or life threatening have been reported. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> usually resolves within a week upon discontinuation of sulfamethoxazole and trimethoprim.<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">Streptococcal Infections</span> and <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span></span><br><br>The sulfonamides should not be used for treatment of group A Î²-hemolytic <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>. In an established <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, they will not eradicate the streptococcus and, therefore, will not prevent sequelae such as <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>.<br><br><span class="Bold">Clostridium Difficile Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span><br><br><span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including sulfamethoxazole and trimethoprim, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.<br><br><span class="Italics">C. difficile </span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.<br><br>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile, </span>and surgical evaluation should be instituted as clinically indicated.<br><br><span class="Bold">Adjunctive Treatment with Leucovorin for <span class="Italics">Pneumocystis jiroveci</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></span><br><br>Treatment failure and excess mortality were observed when trimethoprim-sulfamethoxazole was used concomitantly with leucovorin for the treatment of HIV positive patients with <span class="Italics">Pneumocystis jiroveci </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in a randomized placebo controlled trial.<span class="Sup">6Â Â </span>Co-administration of trimethoprim-sulfamethoxazole and leucovorin during treatment of <span class="Italics">Pneumocystis jiroveci </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> should be avoided.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Section_6"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="Section_6.1"></a><a name="section-7.1"></a><p></p>
<h2>Development of Drug Resistant Bacteria</h2>
<p class="First">Prescribing sulfamethoxazole and trimethoprim oral suspension in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">Folate Deficiency</span></span><br><br>Sulfamethoxazole and trimethoprim should be given with caution to patients with impaired renal or hepatic function, to those with possible <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span> (e.g., the elderly, chronic alcoholics, patients receiving anticonvulsant therapy, patients with <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption syndrome</span>, and patients in <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span> states) and to those with severe allergies or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.<br><br>Hematological changes indicative of <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folic acid deficiency</span> may occur in elderly patients or in patients with preexisting <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folic acid deficiency</span> or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>. These effects are reversible by folinic acid therapy.<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span></span><br><br>In glucose-6-phosphate dehydrogenase deficient individuals, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> may occur. This reaction is frequently dose-related (see <span class="Bold"><a href="#Section_2">CLINICAL  PHARMACOLOGY</a>Â </span>and<span class="Bold">Â <a href="#Section_10">DOSAGE AND ADMINISTRATION</a></span>).<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span><br><br>Cases of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in non-diabetic patients treated with sulfamethoxazole and trimethoprim are seen rarely, usually occurring after a few days of therapy. Patients with renal dysfunction, liver disease, <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span> or those receiving high doses of sulfamethoxazole and trimethoprim are particularly at risk.<br><br><span class="Bold">Phenylalanine Metabolism</span><br><br>Trimethoprim has been noted to impair phenylalanine metabolism, but this is of no significance in phenylketonuric patients on appropriate dietary restriction.<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">Porphyria</span> and <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></span><br><br>As with all drugs containing sulfonamides, caution is advisable in patients with <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span> or thyroid dysfunction.<br><br><span class="Bold">Use in the Treatment of and Prophylaxis for <span class="Italics">Pneumocystis jiroveci</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> in Patients with <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">Acquired Immunodeficiency Syndrome</span> (AIDS)</span><br><br>AIDS patients may not tolerate or respond to sulfamethoxazole and trimethoprim in the same manner as non-AIDS patients. The incidence of side effects, particularly <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and elevated aminotransferase (transaminase) values, with sulfamethoxazole and trimethoprim therapy in AIDS patients who are being treated for <span class="Italics">P. jiroveciÂ  </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> has been reported to be greatly increased compared with the incidence normally associated with the use of sulfamethoxazole and trimethoprim in non-AIDS patients. Adverse effects are generally less severe in patients receiving sulfamethoxazole and trimethoprim for prophylaxis. A history of mild intolerance to sulfamethoxazole and trimethoprim in AIDS patients does not appear to predict intolerance of subsequent secondary prophylaxis.<span class="Sup">7</span> However, if a patient develops <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any sign of adverse reaction, therapy with sulfamethoxazole and trimethoprim should be reevaluated (see <span class="Bold"><a href="#Section_5">WARNINGS</a></span>).<br><br>Co-administration of sulfamethoxazole and trimethoprim and leucovorin should be avoided with <span class="Italics">P. jiroveciÂ  </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (see <span class="Bold"><a href="#Section_5">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.14"></a><a name="section-7.2"></a><p></p>
<h2>Electrolyte Abnormalities</h2>
<p class="First">High dosage of trimethoprim, as used in patients with <span class="Italics">P. jiroveciÂ  </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, induces a progressive but reversible increase of serum potassium concentrations in a substantial number of patients. Even treatment with recommended doses may cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> when trimethoprim is administered to patients with underlying disorders of potassium metabolism, with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, or if drugs known to induce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> are given concomitantly. Close monitoring of serum potassium is warranted in these patients.<br><br>Severe and symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> can occur in patients receiving sulfamethoxazole and trimethoprim, particularly for the treatment of <span class="Italics">P. jiroveci </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>. Evaluation for <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and appropriate correction is necessary in symptomatic patients to prevent life-threatening complications.<br><br>During treatment, adequate fluid intake and urinary output should be ensured to prevent <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>. Patients who are â€œslow acetylatorsâ€? may be more prone to idiosyncratic reactions to sulfonamides.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_6.2"></a><a name="section-7.3"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including sulfamethoxazole and trimethoprim oral suspension should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. It does not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When sulfamethoxazole and trimethoprim oral suspension is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by sulfamethoxazole and trimethoprim oral suspension or other antibacterial drugs in the future.<br><br>Patients should be instructed to maintain an adequate fluid intake in order to prevent <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> and stone formation.<br><br><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="Section_6.3"></a><a name="section-7.4"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Complete blood counts should be done frequently in patients receiving sulfamethoxazole and trimethoprim; if a significant reduction in the count of any formed blood element is noted, sulfamethoxazole and trimethoprim should be discontinued. Urinalyses with careful microscopic examination and renal function tests should be performed during therapy, particularly for those patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_6.4"></a><a name="section-7.5"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Potential for Sulfamethoxazole and Trimethoprim to Affect Other Drugs<br><br>Trimethoprim is an inhibitor of CYP2C8 as well as OCT2 transporter. Sulfamethoxazole is an inhibitor of CYP2C9. Caution is recommended when sulfamethoxazole and trimethoprim is co-administered with drugs that are substrates of CYP2C8 and 2C9 or OCT2.<br><br>In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> has been reported.<br><br>It has been reported that sulfamethoxazole and trimethoprim may prolong the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients who are receiving the anticoagulant warfarin (a CYP2C9 substrate). This interaction should be kept in mind when sulfamethoxazole and trimethoprim is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed.<br><br>Sulfamethoxazole and trimethoprim may inhibit the hepatic metabolism of phenytoin (a CYP2C9 substrate). Sulfamethoxazole and trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect.<br><br>Sulfonamides can also displace methotrexate from plasma protein binding sites and can compete with the renal transport of methotrexate, thus increasing free methotrexate concentrations.<br><br>There have been reports of marked but reversible <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> with coadministration of sulfamethoxazole and trimethoprim and cyclosporine in renal transplant recipients.<br><br>Increased digoxin blood levels can occur with concomitant sulfamethoxazole and trimethoprim therapy, especially in elderly patients. Serum digoxin levels should be monitored.<br><br>Increased sulfamethoxazole blood levels may occur in patients who are also receiving indomethacin.<br><br>Occasional reports suggest that patients receiving pyrimethamine as <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> prophylaxis in doses exceeding 25 mg weekly may develop <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> if sulfamethoxazole and trimethoprim is prescribed.<br><br>The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim.<br><br>Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally <span class="Italics">via </span>OCT2 (e.g., metformin). Additional monitoring of blood glucose may be warranted.<br><br>In the literature, a single case of toxic <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> has been reported after concomitant intake of sulfamethoxazole and trimethoprim and amantadine (an OCT2 substrate). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.<br><br>In the literature, three cases of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> in elderly patients have been reported after concomitant intake of sulfamethoxazole and trimethoprim and an angiotensin converting enzyme inhibitor.<span class="Sup">8,9</span></p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="Section_6.5"></a><a name="section-7.6"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Sulfamethoxazole and trimethoprim, specifically the trimethoprim component, can interfere with a serum methotrexate assay as determined by the competitive binding protein technique (CBPA) when a bacterial dihydrofolate reductase is used as the binding protein. No interference occurs, however, if methotrexate is measured by a radioimmunoassay (RIA).<br><br>The presence of sulfamethoxazole and trimethoprim may also interfere with the JaffÃ© alkaline picrate reaction assay for creatinine, resulting in overestimations of about 10% in the range of normal values.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_6.6"></a><a name="section-7.7"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenesis<br><br>Sulfamethoxazole was not carcinogenic when assessed in a 26-week tumorigenic mouse (Tg-rasH2) study at doses up to 400 mg/kg/day sulfamethoxazole; equivalent to 2.4-fold the human systemic exposure (at a daily dose of 800 mg sulfamethoxazole <span class="Italics">b.i.d.</span>).<br><br>Mutagenesis<br><br><span class="Italics">In vitro </span>reverse mutation bacterial tests according to the standard protocol have not been performed with sulfamethoxazole and trimethoprim in combination. An <span class="Italics">in vitro </span>chromosomal aberration test in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> with sulfamethoxazole and trimethoprim was negative. In <span class="Italics">in vitro </span>and <span class="Italics">in vivo </span>tests in animal species, sulfamethoxazole and trimethoprim did not damage chromosomes. <span class="Italics">In vivo </span>micronucleus assays were positive following oral administration of sulfamethoxazole and trimethoprim. Observations of leukocytes obtained from patients treated with sulfamethoxazole and trimethoprim revealed no chromosomal abnormalities.<br><br>Sulfamethoxazole alone was positive in an <span class="Italics">in vitro </span>reverse mutation bacterial assay and in <span class="Italics">in vitro </span>micronucleus assays using cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.<br><br>Trimethoprim alone was negative in <span class="Italics">in vitro </span>reverse mutation bacterial assays and in <span class="Italics">in vitro </span>chromosomal aberration assays with Chinese Hamster ovary or lung cells with or without S9 activation. In <span class="Italics">in vitro </span>Comet, micronucleus and chromosomal damage assays using cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, trimethoprim was positive. In mice following oral administration of trimethoprim, no DNA damage in Comet assays of liver, kidney, lung, spleen, or bone marrow was recorded.<br><br>Impairment of Fertility<br><br>No adverse effects on fertility or general reproductive performance were observed in rats given oral dosages as high as 350 mg/kg/day sulfamethoxazole plus 70 mg/kg/day trimethoprim, doses roughly two times the recommended human daily dose on a body surface area basis.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_6.7"></a><a name="section-7.8"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">While there are no large, well-controlled studies on the use of sulfamethoxazole and trimethoprim in pregnant women, Brumfitt and Pursell,<span class="Sup">10Â </span>in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or sulfamethoxazole and trimethoprim. The incidence of congenital abnormalities was 4.5% (3 of 66) in those who received placebo and 3.3% (4 of 120) in those receiving sulfamethoxazole and trimethoprim. There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received oral sulfamethoxazole and trimethoprim at the time of conception or shortly thereafter.<br><br>Because sulfamethoxazole and trimethoprim may interfere with folic acid metabolism, sulfamethoxazole and trimethoprim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<div class="Section" data-sectionCode="34077-8">
<a name="Section_6.7.1"></a><a name="section-7.8.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects</span></h3>
<p class="First"><span class="Italics">Pregnancy Category D</span><br><br><span class="Bold">Human Data</span><br><br>While there are no large prospective, well controlled studies in pregnant women and their babies, some retrospective epidemiologic studies suggest an association between first trimester exposure to sulfamethoxazole and trimethoprim with an increased risk of congenital malformations, particularly <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span>, cardiovascular abnormalities, urinary tract defects, oral clefts, and club foot. These studies, however, were limited by the small number of exposed cases and the lack of adjustment for multiple statistical comparisons and confounders. These studies are further limited by recall, selection, and information biases, and by limited generalizability of their findings. Lastly, outcome measures varied between studies, limiting cross-study comparisons. Alternatively, other epidemiologic studies did not detect statistically significant associations between sulfamethoxazole and trimethoprim exposure and specific malformations.<br><br><span class="Bold">Animal Data</span><br><br>In rats, oral doses of either 533 mg/kg sulfamethoxazole or 200 mg/kg trimethoprim produced teratologic effects manifested mainly as <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span>. These doses are approximately 5 and 6 times the recommended human total daily dose on a body surface area basis. In two studies in rats, no teratology was observed when 512 mg/kg of sulfamethoxazole was used in combination with 128 mg/kg of trimethoprim. In some rabbit studies, an overall increase in fetal loss (dead and resorbed conceptuses) was associated with doses of trimethoprim 6 times the human therapeutic dose based on body surface area. </p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="Section_6.7.2"></a><a name="section-7.8.2"></a><p></p>
<h3><span class="Bold">Nonteratogenic Effects</span></h3>
<p class="First">See <span class="Bold"><a href="#Section_4">CONTRAINDICATIONS</a>Â </span>section.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_6.9"></a><a name="section-7.9"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Levels of trimethoprim and sulfamethoxazole in breast milk are approximately 2 to 5% of the recommended daily dose for infants over 2 months of age. Caution should be exercised when sulfamethoxazole and trimethoprim is administered to a nursing woman, especially when breastfeeding, jaundiced, ill, stressed, or premature infants because of the potential risk of bilirubin displacement and <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span>.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_6.10"></a><a name="section-7.10"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Sulfamethoxazole and trimethoprim is contraindicated for infants younger than 2 months of age (see <span class="Bold"><a href="#Section_3">INDICATIONS</a>Â </span>and <span class="Bold"><a href="#Section_4">CONTRAINDICATIONS</a></span> sections).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_6.11"></a><a name="section-7.11"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of sulfamethoxazole and trimethoprim did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.<br><br>There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, e.g., impaired kidney and/or liver function, possible <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>, or concomitant use of other drugs. Severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, generalized bone marrow suppression (see <span class="Bold"><a href="#Section_5">WARNINGS</a></span> and <span class="Bold"><a href="#Section_7">ADVERSE REACTIONS</a></span> sections), a specific decrease in platelets (with or without <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>), and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving certain diuretics, primarily thiazides, an increased incidence of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> has been reported. Increased digoxin blood levels can occur with concomitant sulfamethoxazole and trimethoprim therapy, especially in elderly patients. Serum digoxin levels should be monitored. Hematological changes indicative of <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folic acid deficiency</span> may occur in elderly patients. These effects are reversible by folinic acid therapy. Appropriate dosage adjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions (see <span class="Bold"><a href="#Section_10">DOSAGE AND ADMINISTRATION</a></span> section). The trimethoprim component of sulfamethoxazole and trimethoprim may cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> when administered to patients with underlying disorders of potassium metabolism, with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> or when given concomitantly with drugs known to induce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, such as angiotensin converting enzyme inhibitors. Close monitoring of serum potassium is warranted in these patients. Discontinuation of sulfamethoxazole and trimethoprim treatment is recommended to help lower potassium serum levels.<br><br>Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects. The mean maximum serum trimethoprim concentration was higher and mean renal clearance of trimethoprim was lower in geriatric subjects compared with younger subjects (see <span class="Bold"><a href="#Section_2.1">CLINICAL PHARMACOLOGY: Geriatric Pharmacokinetics</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_7"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most common adverse effects are <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>) and <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reactions</span> (such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>). <span class="Bold">FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">STEVENS-JOHNSON SYNDROME</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">TOXIC EPIDERMAL NECROLYSIS</span>, FULMINANT <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">HEPATIC NECROSIS</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">APLASTIC ANEMIA</span> AND OTHER <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">BLOOD DYSCRASIAS</span> (SEE <a href="#Section_5">WARNINGS</a> SECTION).</span><br><br><span class="Bold">Hematologic</span><br><br><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>, <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span><br><br><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, allergic <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, Henoch-Schoenlein <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like syndrome, generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, conjunctival and scleral injection, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. In addition, <span class="product-label-link" type="condition" conceptid="320749" conceptname="Polyarteritis nodosa">periarteritis nodosa</span> and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> have been reported.<br><br><span class="Bold">Gastrointestinal</span><br><br><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> (including <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> and <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>), elevation of serum transaminase and bilirubin, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.<br><br><span class="Bold">Genitourinary</span><br><br><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, BUN and serum creatinine elevation, toxic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span> with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> in association with cyclosporine.<br><br><span class="Bold">Metabolic and Nutritional</span><br><br><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>, hyponatremiaÂ Â (see <span class="Bold"><a href="#Section_6.14">PRECAUTIONS: Electrolyte Abnormalities</a></span>).Â Â Â <br><br><span class="Bold">Neurologic</span><br><br><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuritis</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.Â <br><br><span class="Bold">Psychiatric</span><br><br><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>.<br><br><span class="Bold">Endocrine</span><br><br>The sulfonamides bear certain chemical similarities to some goitrogens, diuretics (acetazolamide and the thiazides) and oral hypoglycemic agents. Cross-sensitivity may exist with these agents. <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">Diuresis</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> have occurred rarely in patients receiving sulfonamides.<br><br><span class="Bold">Musculoskeletal</span><br><br><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>. Isolated cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported with sulfamethoxazole and trimethoprim, mainly in AIDS patients.<br><br><span class="Bold">Respiratory</span><br><br><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> and pulmonary infiltrates (see <span class="Bold"><a href="#Section_5">WARNINGS</a></span>).<br><br><span class="Bold">Miscellaneous</span><br><br><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.<br><br><span class="Bold">Postmarketing Experience</span><br><br>The following adverse reactions have been identified during post-approval use of trimethoprim-sulfamethoxazole. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure:Â </p>
<dl>
<dt>â€¢</dt>
<dd>Thrombotic <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenia purpura</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">Idiopathic thrombocytopenic purpura</span></dd>
<dt>â€¢</dt>
<dd>QT prolongation resulting in <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="Italics"><span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span></span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_9"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="Bold">Acute</span><br><br>The amount of a single dose of sulfamethoxazole and trimethoprim that is either associated with symptoms of overdosage or is likely to be life-threatening has not been reported. Signs and symptoms of overdosage reported with sulfonamides include <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> and <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> may be noted. <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood dyscrasias</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> are potential late manifestations of overdosage.<br><br>Signs of acute overdosage with trimethoprim include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>.<br><br>General principles of treatment include the institution of gastric lavage or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, forcing oral fluids, and the administration of intravenous fluids if urine output is low and renal function is normal. Acidification of the urine will increase renal elimination of trimethoprim. The patient should be monitored with blood counts and appropriate blood chemistries, including electrolytes. If a significant <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurs, specific therapy should be instituted for these complications. Peritoneal dialysis is not effective and hemodialysis is only moderately effective in eliminating sulfamethoxazole and trimethoprim.<br><br><span class="Bold">Chronic</span><br><br>Use of sulfamethoxazole and trimethoprim at high doses and/or for extended periods of time may cause <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> manifested as <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and/or <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>. If signs of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> occur, the patient should be given leucovorin 5 to 15 mg daily until normal hematopoiesis is restored.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_10"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Sulfamethoxazole and trimethoprim oral suspension is contraindicated in pediatric patients less than 2 months of age.</span><br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> and Shigellosis in Adults and Pediatric Patients, and Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> in Children</span><br><br>Adults<br><br>The usual adult dosage in the treatment of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> is four teaspoonfuls (20 mL) sulfamethoxazole and trimethoprim oral suspension every 12 hours for 10 to 14 days. An identical daily dosage is used for 5 days in the treatment of shigellosis.<br><br>Children<br><br>The recommended dose for children with <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> or acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> is 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours, given in two divided doses every 12 hours for 10 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. The following table is a guideline for the attainment of this dosage:<br><br><span class="Italics">Children 2 months of age or older:</span></p>
<table>
<col width="28%">
<col width="28%">
<col width="43%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First">Weight<br></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">Doseâ€“every 12 hours<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">lb<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">kg<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">Teaspoonfuls<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">10<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (5 mL)<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">44<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">20<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (10 mL)<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">66<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">30<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3 (15 mL)<br></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">88<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">40<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 (20 mL)<br></p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">For Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span><br><br>When renal function is impaired, a reduced dosage should be employed using the following table:</p>
<table>
<col width="49%">
<col width="49%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Creatinine Clearance (mL/min)<br></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">Recommended Dosage Regimen<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Above 30<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">Usual standard regimen<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15 to 30<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">Â½ the usual regimen<br></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">Below 15<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">Use not recommended<br></p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Acute Exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span> in Adults</span><br><br>The usual adult dosage in the treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> is four teaspoonfuls (20 mL) sulfamethoxazole and trimethoprim oral suspension every 12 hours for 14 days.<br><br><span class="Italics">Pneumocystis Jiroveci</span>Â  <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span><br><br>Treatment<br><br><span class="Italics">Adults and Children</span><br><br>The recommended dosage for treatment of patients with documented <span class="Italics">PneumocystisÂ jiroveci </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> is 75 to 100 mg/kg sulfamethoxazole and 15 to 20 mg/kg trimethoprim per 24 hours given in equally divided doses every 6 hours for 14 to 21 days.<span class="Sup">11</span> The following table is a guideline for the upper limit of this dosage:</p>
<table>
<col width="28%">
<col width="28%">
<col width="43%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First">Weight<br></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">Doseâ€“every 6 hours<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">lb<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">kg<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">Teaspoonfuls<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">8<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (5 mL)<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">35<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">16<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (10 mL)<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">53<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">24<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3 (15 mL)<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">70<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">32<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 (20 mL)<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">88<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">40<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5 (25 mL)<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">106<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">48<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">6 (30 mL)<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">141<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">64<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">8 (40 mL)<br></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">176<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">80<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">10 (50 mL)<br></p></td>
</tr>
</tbody>
</table>
<p>For the lower limit dose (75 mg/kg sulfamethoxazole and 15 mg/kg trimethoprim per 24 hours) administer 75% of the dose in the above table.<br><br>Prophylaxis<br><br><span class="Italics">Adults</span><br><br>The recommended dosage for prophylaxis in adults is four teaspoonfuls (20 mL) of the suspension daily.<span class="Sup">12</span><br><br><br><span class="Italics">Children</span><br><br>For children, the recommended dose is 750 mg/m<span class="Sup">2</span>/day sulfamethoxazole with 150 mg/m<span class="Sup">2</span>/day trimethoprim given orally in equally divided doses twice a day, on 3 consecutive days per week. The total daily dose should not exceed 1600 mg sulfamethoxazole and 320 mg trimethoprim.<span class="Sup">13</span> The following table is a guideline for the attainment of this dosage in children:</p>
<table>
<col width="49%">
<col width="49%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Body Surface Area<br></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">Doseâ€“every 12 hours<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(m<span class="Sup">2</span>)<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">Teaspoonfuls<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.26<br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">Â½ (2.5 mL)<br></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.53 <br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (5 mL)<br></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.06 <br></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (10 mL)<br></p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Travelerâ€™s <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> in Adults</span><br><br>For the treatment of travelerâ€™s <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, the usual adult dosage is four teaspoonfuls (20 mL) of the suspension every 12 hours for 5 days.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_11"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">Sulfamethoxazole and Trimethoprim Oral Suspension, USP</span> contains 200 mg sulfamethoxazole and 40 mg trimethoprim in each teaspoonful (5 mL). Available as a pink, cherry-flavored syrup suspension.<br><br>473 mL Bottle - 68788-9512-4<br><br><span class="Bold">Store at </span>20Âº to 25ÂºC (68Âº to 77ÂºF) [see USP Controlled Room Temperature] and protect from light.<br><br>SHAKE WELL BEFORE USING.<br><br>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="Section_14"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Kremers P, Duvivier J, Heusghem C. Pharmacokinetic Studies of Co-Trimoxazole in Man after Single and Repeated Doses. <span class="Italics">J Clin Pharmacol</span>. Feb-Mar 1974; 14:112â€“117. </dd>
<dt>2.</dt>
<dd>Kaplan SA, et al. Pharmacokinetic Profile of Trimethoprim-Sulfamethoxazole in Man.<span class="Italics"> J Infect Dis</span>. Nov 1973; 128 (Suppl): S547â€“S555.Â </dd>
<dt>3.</dt>
<dd>Varoquaux O, et al. Pharmacokinetics of the trimethoprim-sulfamethoxazole combination in the elderly.<span class="Italics"> Br J Clin Pharmacol</span>. 1985;20:575â€“581. </dd>
<dt>4.</dt>
<dd>Rudoy RC, Nelson JD, Haltalin KC.<span class="Italics"> Antimicrobial Agents Chemother</span>. May 1974;5:439â€“443.</dd>
<dt>5.</dt>
<dd>Clinical and Laboratory Standards Institute. <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard â€“ 9<span class="Sup">th</span> ed.</span> CLSI document M07â€“ A9, CLSI, Wayne, PA, 2012.</dd>
<dt>6.</dt>
<dd>Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for<span class="Italics"> Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in AIDS patients is associated with an increased risk of therapeutic failure and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.<span class="Italics"> J Infect Dis</span>. 1994 Oct;170(4):912-7. </dd>
<dt>7.</dt>
<dd>Hardy DW, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis o<span class="Italics">f Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in patients with the <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span><span class="Italics">. N Engl J Med</span>. 1992; 327: 1842â€“1848.</dd>
<dt>8.</dt>
<dd>Marinella Mark A. 1999. Trimethoprim-induced <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>: An analysis of reported cases.<span class="Italics"> Gerontol</span>. 45:209â€“212.</dd>
<dt>9.</dt>
<dd>Margassery, S. and B. Bastani. 2002. Life threatening <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> secondary to trimethoprim-sulfamethoxazole treatment<span class="Italics">. J. Nephrol</span>. 14:410â€“414.</dd>
<dt>10.</dt>
<dd>Brumfitt W, Pursell R. Trimethoprim/Sulfamethoxazole in the Treatment of <span class="product-label-link" type="condition" conceptid="4265485" conceptname="Bacteriuria">Bacteriuria</span> in Women.<span class="Italics"> J Infect Dis</span>. Nov 1973; 128 (Suppl):S657â€“S663.</dd>
<dt>11.</dt>
<dd>Masur H. Prevention and treatment o<span class="Italics">f Pneumocystis </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span><span class="Italics">. N Engl J Med</span>. 1992; 327: 1853â€“1880.</dd>
<dt>12.</dt>
<dd>Recommendations for prophylaxis agains<span class="Italics">t Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> for adults and adolescents infected with human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus<span class="Italics">. MMWR. </span>1992; 41(RR-4):1â€“11. </dd>
<dt>13.</dt>
<dd>CDC Guidelines for prophylaxis agains<span class="Italics">t Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> for children infected with human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus<span class="Italics">. MMWR</span>. 1991; 40(RR-2):1â€“13. </dd>
<dt>14.</dt>
<dd>Clinical and Laboratory Standards Institute. <span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard â€“ 11<span class="Sup">th</span> ed.</span> CLSI document M02â€“A11, CLSI, Wayne, PA, 2012.</dd>
<dt>15.</dt>
<dd>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing; Twenty-third Informational Supplement</span>, CLSI document M100â€“S23. CLSI document M100â€“S23, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2013. </dd>
</dl>
<p class="First">Manufactured for:<br><span class="Bold">Aurobindo Pharma USA, Inc.</span><br>2400 Route 130 North<br>Dayton, NJ 08810<br><br>Manufactured by:<br><span class="Bold">Aurobindo Pharma Limited</span><br>Hyderabad-500 072, India<br><br>Revised: 09/2013</p>
<p><span class="Bold">Relabeled by Preferred Pharmaceuticals, Inc.</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_18"></a><a name="section-13"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 200 mg/40 mg per 5 mL</h1>
<p class="First"><br><span class="Bold">Sulfamethoxazole and Trimethoprim Oral Suspension, USP</span><br><span class="Bold">200 mg/40 mg per 5 mL</span><br><span class="Bold">Rx only</span></p>
<div class="Figure">
<a name="id1410"></a><img alt="Sulfamethoxazole &amp; Trimethoprim Oral Suspension" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bbad2036-e2a8-4c56-bb92-dea833598ebc&amp;name=bbad2036-e2a8-4c56-bb92-dea833598ebc-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SULFAMETHOXAZOLE AND TRIMETHOPRIMÂ 		
					</strong><br><span class="contentTableReg">sulfamethoxazole and trimethoprim suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68788-9512(NDC:65862-496)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SULFAMETHOXAZOLE</strong> (SULFAMETHOXAZOLE) </td>
<td class="formItem">SULFAMETHOXAZOLE</td>
<td class="formItem">200Â mg Â inÂ 5Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>TRIMETHOPRIM</strong> (TRIMETHOPRIM) </td>
<td class="formItem">TRIMETHOPRIM</td>
<td class="formItem">40Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68788-9512-4</td>
<td class="formItem">473 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091348</td>
<td class="formItem">02/12/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Preferred Pharmaceuticals, Inc.
							(791119022)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aurobindo Pharma Limited</td>
<td class="formItem"></td>
<td class="formItem">918917642</td>
<td class="formItem">RELABEL(68788-9512)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bbad2036-e2a8-4c56-bb92-dea833598ebc</div>
<div>Set id: bbad2036-e2a8-4c56-bb92-dea833598ebc</div>
<div>Version: 1</div>
<div>Effective Time: 20140219</div>
</div>
</div>Â <div class="DistributorName">Preferred Pharmaceuticals, Inc.</div></p>
</body></html>
